According to a report by the US “Qiaoqiao.com” on August 14, researchers at the University of Alabama at Birmingham (UAB) found that a drug ingredient extracted from cannabis, Cannabidiol (also known as CBD), Treatment of drug-resistant epilepsy is effective. The study was published in the journal Epilepsy and Behavior.
According to the United Press International, the researchers pointed out in the report that CBD can effectively reduce the number of episodes of patients with epilepsy who are resistant to traditional therapy.
The US Food and Drug Administration (FDA) approved "Epidiolex" in June for the treatment of two rare drug-resistant epilepsy. This is also the first time the FDA has approved the use of purified drugs extracted from cannabis. The drug contains only traces of tetrahydrocannabinol (THC), which is also the toxic component of hallucinogenic addiction contained in cannabis.
Dr. Martina Bebin, a researcher and professor of neurology at UAB Medical School, said that they registered all patients with various treatment-resistant epilepsy in the study. The results showed that CBD may be resistant to the whole. Epilepsy is effective within the scope of the disease.
The study began in 2015 when the Alabama legislature approved the Carly's Law, which authorizes UAB and the Alabama Children's Epilepsy Center to study with cannabinol. The study participants included 132 patients, including 72 children and 60 adults.
During the first 12 weeks of the study, the frequency of participants' episodes decreased from 144 to 52 episodes per two weeks and remained stable throughout the 48-week study.
"In the study, most patients experienced a significant reduction in seizures," Beckin said. "There was almost a two-third reduction in the overall study population, and some patients had even more frequent seizures. At the same time, the overall seizures of participants were severe. The degree has also been greatly reduced."
Dr. Jerzy Szaflarski, director of the UCSB epilepsy center, noted that the results of the study were clinically significant and that most participants showed an improvement of 50% to 60%, and there were few participants in the treatment process. side effect.
